Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions

Tenapanor (RDX5791, AZD1722) is an inhibitor of sodium/hydrogen exchanger isoform 3 in development for the treatment of constipation‐predominant irritable bowel syndrome and the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. We aimed to investigate whether tenapa...

Descripción completa

Detalles Bibliográficos
Autores principales: Johansson, Susanne, Rosenbaum, David P., Ahlqvist, Marie, Rollison, Helen, Knutsson, Mikael, Stefansson, Bergur, Elebring, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599994/
https://www.ncbi.nlm.nih.gov/pubmed/28301096
http://dx.doi.org/10.1002/cpdd.346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599994/
https://www.ncbi.nlm.nih.gov/pubmed/28301096
http://dx.doi.org/10.1002/cpdd.346

Ejemplares similares